A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AstroStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Patients With Alzheimer's Disease
Overview
- Phase
- Phase 1
- Intervention
- AstroStem
- Conditions
- Alzheimer Disease
- Sponsor
- Nature Cell Co. Ltd.
- Enrollment
- 21
- Locations
- 3
- Primary Endpoint
- Treatment Related Adverse Events
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with Alzheimer's Disease. Following first screening period, subjects will be randomly assigned into one of the following arms: AstroStem and placebo control in a 1:1 ratio. AstroStem or placebo control will be administered via I.V. at Week 0. This procedure will be repeated 9 times at 2-week interval. Subjects will be scheduled for two follow-up visits at Weeks 30 and 52 to evaluate primary and secondary outcome endpoints.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female subjects aged 50 and above at the time of signing the Informed Consent form
- •Subjects who can understand and provide written informed consent (assent)
- •Subjects who have diagnosis of probable mild-to-moderate Alzheimer disease according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke; Alzheimer's Disease and Related Disorders Association) criteria
- •Subjects who have MMSE Score of 16 to 26 at screening
- •Subjects who are taking FDA-approved AD medications (donepezil, galantamine, memantine, rivastigmine or their combinations) treatment on a stable dosage for at least 3 months prior to screening.
- •Subjects who have one (or more) identified adult caregiver who is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for ≥2 hours/day ≥4 days/week; and agrees to accompany the subject to each study visit
- •Subjects who have a designated study partner who will accompany the subject to all clinic visits and participate in the subject's clinical assessments
Exclusion Criteria
- •Subjects who are females who are pregnant, nursing, or of childbearing potential while not practicing effective contraception
- •Subjects who have signs of delirium
- •Subjects who have had cortical stroke within the preceding 2 years
- •Subjects who have a prolonged QTc interval; \>450 msec in male or \>470 msec in female at screening
- •Subjects who have diagnosis of severe white matter hyperintensity (WMH), which is defined as ≥ 25mm of the deep white matter and ≥ 10mm of the periventricular capping/banding in lengths
- •Subjects who have diagnosis of dementia or cause of cognitive impairment other than Alzheimer's disease
- •Subjects who have a significant abnormal result in laboratory tests, in the opinion of the investigator
- •Subjects who have participated in any investigational drug, stem cell therapy, or device trial within the previous 3 months at screening
- •Subjects with any current psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the subject´s ability to complete the study
- •Subjects who are known to have autosomal dominant mutation-associated presenile AD
Arms & Interventions
AstroStem
Intervention: AstroStem
Placebo-Control
Intervention: Placebo-Control
Outcomes
Primary Outcomes
Treatment Related Adverse Events
Time Frame: 30 Weeks
Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results
ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)
Time Frame: Baseline and 30 Weeks
Change of ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale) from Baseline at Week 30 Score range: 0-70 A score of 70 represents the most severe impairment and 0 represents the least impairment
Secondary Outcomes
- MMSE (Mini-mental Status Examination)(Baseline and 30 Weeks)
- NPI (Neuropsychiatric Inventory)(Baseline and 30 Weeks)
- CDR-SOB (Clinical Dementia Rating-Sum of Boxes)(Baseline and 30 Weeks)
- GDS (Geriatric Depression Scale)(Baseline and 30 Weeks)
- ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)(Baseline and 30 Weeks)
- C-SSRS (Columbia Suicide Severity Rating Scale)(Baseline and 30 Weeks)